SCHEMBL4422170

SCHEMBL4422170

CSc1nc(-c2cccc(N)c2)c2c(N)c(C(N)=O)c(C(C)(C)C)cc2n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LHCGR P22888 6/20 0.42
TSHR P16473 1/20 0.41
CSNK1E P49674 2/20 0.39
CSNK1D P48730 1/20 0.39
BRAF P15056 1/20 0.36
PDE4A P27815 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36
RIPK2 O43353 3/20 0.35
FSHR P23945 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
SRC P12931 1/20 0.33
PARP1 P09874 1/20 0.32
PLK4 O00444 1/20 0.32
MAP4K4 O95819 1/20 0.32
EGFR P00533 1/20 0.32
ROS1 P08922 1/20 0.32
PIM1 P11309 1/20 0.32
AXL P30530 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4430425 0.91 LHCGR (0.52) LHCGRTSHRCSNK1EBRAFPDE4A
SCHEMBL4423876 0.88 LHCGR (0.56) LHCGRTSHRBRAFPDE4APDE4B
SCHEMBL4425814 0.84 LHCGR (0.40) LHCGRTSHRBRAFFSHRMAP4K4
SCHEMBL4432379 0.80 LHCGR (0.43) LHCGRTSHRCSNK1ECSNK1DBRAF
SCHEMBL4423221 0.75 LHCGR (0.41) LHCGRTSHRBRAFPDE4APDE4B
SCHEMBL4422167 0.75 LHCGR (0.55) LHCGRTSHRCSNK1ECSNK1DBRAF
SCHEMBL4421145 0.72 BRAF (0.62) LHCGRTSHRBRAFPDE4APDE4B
SCHEMBL4421572 0.71 SMN1; SMN2 (0.50) LHCGRTSHRCSNK1DSMN1; SMN2KDM4E
SCHEMBL4423903 0.70 LHCGR (0.54) LHCGRTSHRCSNK1ECSNK1DBRAF
SCHEMBL5025967 0.68 LHCGR (0.62) LHCGRTSHRBRAFPDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7618963-B2 Bicyclic heteroaromatic compounds N.V. ORGANON (NL) 2009-11-17 US disclosed
EP-1886999-A2 Bicyclic heteroaromatic compound N.V. Organon (NL) 2008-02-13 EP disclosed
US-20070197527-A1 Bicyclic heteroaromatic compounds N.V. ORGANON (NL) 2007-08-23 US disclosed
US-7229990-B2 Bicyclic heteroaromatic compounds N.V. ORGANON (NL) 2007-06-12 US disclosed
US-20030225113-A1 Bicyclic heteroaromatic compounds MERCK SHARP & DOHME B.V. (NL) 2003-12-04 US disclosed
EP-1322651-A1 BICYCLIC HETEROAROMATIC COMPOUNDS Akzo Nobel N.V. (NL) 2003-07-02 EP disclosed
WO-2002024703-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AKZO NOBEL N.V. (NL) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225113-A1 Bicyclic heteroaromatic compounds NR5A1, CYP19A1, FSHR LHCGR 13/4885TSHR 1000/4885CSNK1E 1216/4885
US-20070197527-A1 Bicyclic heteroaromatic compounds NR5A1, CYP19A1, FSHR LHCGR 10/4885TSHR 517/4885CSNK1E 1248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.